BioSpace News Archive

ENYO Pharma (“ENYO”) announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical study of Vonafexor, a highly selective FXR agonist, for the treatment of Alport Syndrome.

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 7:30 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.

Ultragenyx Pharmaceutical Inc. today announced the completion of patient enrollment in its Phase 1/2 clinical trial of GTX-102 for the treatment of pediatric patients with Angelman syndrome (AS).

VYNE Therapeutics Inc. today announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024.

Mesa Laboratories, Inc. announced the completed acquisition of GKE-GmbH’s sterilization indicators business and its accredited, independent testing lab SAL GmbH on October 16th, 2023.

DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Wednesday, January 10, 2024, at 7:30 am PT (10:30 am ET).

Erasca, Inc. today announced its participation in the 42nd annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA.

Noema Pharma today announced that members of management will attend and present at two upcoming conferences in San Francisco, CA.

Pulmocide Ltd. today announced that Dan Burgess, Chairman and CEO, will present a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 from 5:00pm – 5:25pm PT in San Francisco.

STRATA Skin Sciences, Inc. announced that it has received a notification letter from Nasdaq Stock Market LLC that the Company has been granted a 180-day extension, or until June 24, 2024, to regain compliance with Nasdaq’s minimum bid price rule.